Acura Pharmaceuticals Inc
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminoph… Read more
Acura Pharmaceuticals Inc (ACUR) - Net Assets
Latest net assets as of September 2021: $135.00K USD
Based on the latest financial reports, Acura Pharmaceuticals Inc (ACUR) has net assets worth $135.00K USD as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.41 Million) and total liabilities ($1.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $135.00K |
| % of Total Assets | 9.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -99.36% |
| Growth Volatility | 62.0 |
Acura Pharmaceuticals Inc - Net Assets Trend (2000–2021)
This chart illustrates how Acura Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Acura Pharmaceuticals Inc (2000–2021)
The table below shows the annual net assets of Acura Pharmaceuticals Inc from 2000 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $178.00K | +103.02% |
| 2020-12-31 | $-5.89 Million | -24.26% |
| 2019-12-31 | $-4.74 Million | -31.08% |
| 2018-12-31 | $-3.62 Million | -13296.30% |
| 2017-12-31 | $-27.00K | -102.28% |
| 2016-12-31 | $1.18 Million | -85.03% |
| 2015-12-31 | $7.90 Million | +56.37% |
| 2014-12-31 | $5.05 Million | -71.81% |
| 2013-12-31 | $17.92 Million | -35.13% |
| 2012-12-31 | $27.63 Million | -24.60% |
| 2011-12-31 | $36.64 Million | +50.54% |
| 2010-12-31 | $24.34 Million | -18.62% |
| 2009-12-31 | $29.91 Million | -19.30% |
| 2008-12-31 | $37.06 Million | +97.99% |
| 2007-12-31 | $18.72 Million | +148.90% |
| 2006-12-31 | $-38.28 Million | -521.23% |
| 2005-12-31 | $-6.16 Million | -467.93% |
| 2004-12-31 | $-1.08 Million | +97.92% |
| 2003-12-31 | $-52.07 Million | -324.41% |
| 2002-12-31 | $-12.27 Million | +81.25% |
| 2001-12-31 | $-65.44 Million | -22.66% |
| 2000-12-31 | $-53.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acura Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39008300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $390.26 Million | 219247.75% |
| Total Equity | $178.00K | 100.00% |
Acura Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Acura Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZIL Ltd
KAR:ZIL
|
$13.20K |
|
Record PLC
LSE:REC
|
$13.21K |
|
PAVmed Inc. Series Z Warrant
NASDAQ:PAVMZ
|
$13.21K |
|
CRFB3F
SA:CRFB3F
|
$13.21K |
|
HAPV3F
SA:HAPV3F
|
$13.19K |
|
HB Solution Co. Ltd.
KO:297890
|
$13.18K |
|
Inflection Point Acquisition Corp. II Warrant
NASDAQ:IPXXW
|
$13.16K |
|
King House CO., Ltd.
TWO:4419
|
$13.14K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acura Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from -5,891,000 to 178,000, a change of 6,069,000.
- Net loss of 879,000 reduced equity.
- New share issuances of 3,000 increased equity.
- Other factors increased equity by 6,945,000.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-879.00K | -493.82% |
| Share Issuances | $3.00K | +1.69% |
| Other Changes | $6.95 Million | +3901.69% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Acura Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.05x to 7.24x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.37 | $0.02 | x |
| 2015-12-31 | $0.67 | $0.02 | x |
| 2016-12-31 | $0.10 | $0.02 | x |
| 2017-12-31 | $0.00 | $0.02 | x |
| 2018-12-31 | $-0.17 | $0.02 | x |
| 2019-12-31 | $-0.22 | $0.02 | x |
| 2020-12-31 | $-0.27 | $0.02 | x |
| 2021-12-31 | $0.00 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acura Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -493.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -56.24%
- • Asset Turnover: 1.82x
- • Equity Multiplier: 4.83x
- Recent ROE (-493.82%) is below the historical average (-124.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 39.05% | 32.57% | 1.03x | 1.16x | $10.77 Million |
| 2011 | 28.34% | 50.74% | 0.55x | 1.01x | $6.72 Million |
| 2012 | -34.99% | 0.00% | 0.00x | 1.05x | $-12.43 Million |
| 2013 | -77.56% | -11301.63% | 0.00x | 1.60x | $-15.69 Million |
| 2014 | -261.46% | -1758.85% | 0.05x | 3.17x | $-13.71 Million |
| 2015 | -63.15% | -58.10% | 0.51x | 2.15x | $-5.78 Million |
| 2016 | -624.51% | -165.50% | 0.54x | 6.94x | $-7.51 Million |
| 2017 | 0.00% | -191.57% | 0.64x | 0.00x | $-5.68 Million |
| 2018 | 0.00% | -937.07% | 0.19x | 0.00x | $-3.48 Million |
| 2019 | 0.00% | -142.04% | 1.04x | 0.00x | $-3.30 Million |
| 2020 | 0.00% | -33.84% | 2.06x | 0.00x | $-618.90K |
| 2021 | -493.82% | -56.24% | 1.82x | 4.83x | $-896.80K |
Industry Comparison
This section compares Acura Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $484,957,697
- Average return on equity (ROE) among peers: -35.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acura Pharmaceuticals Inc (ACUR) | $135.00K | 39.05% | 9.41x | $13.20K |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |